78% of moderate aortic stenosis patients have high-risk features that double mortality and heart failure hospitalization risk within two years, study shows.
Eton Pharma's ET-900 program tests mecasermin injection for refractory infantile spasms, with first patient dosing planned for Q1 2027.
PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...
Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...
The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...
PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...
Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...
ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...
PharPoint Research shaped Medrio CTMS design through early adopter program, influencing clinical trial monitoring workflows ...
Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...
Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results